Leukemia, Myeloid Clinical Trial
Official title:
An Open-Label Study of CEP-701 in Patients With Refractory, Relapsed, or Poor Risk Acute Myeloid Leukemia Expressing FLT-3 Activating Mutations
The purpose of this study is to determine the response rate of patients with refractory, relapsed or poor risk AML expressing FLT-3 activating mutations, when administered CEP-701 at a dosage of 60 mg 2 times a day.
This is an open-label study of CEP-701 in patients with refractory, relapsed, or poor risk AML expressing FLT-3 activating mutations. Patients who meet eligibility criteria will be enrolled at a dosage of 60 mg orally 2 times a day for 28 days (1 cycle). Upon completion of cycle 1, the dosage may be increased to 80mg 2 times a day or decreased to 40 mg 2 times a day, dependent upon response to 60 mg dosage. ;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT04265963 -
CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
Completed |
NCT00233909 -
A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
Terminated |
NCT04748848 -
A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy
|
Phase 1 | |
Completed |
NCT04039100 -
Family Caregiver Ambassador Support for Family Caregivers of Patients With Hematological Disease
|
N/A | |
Recruiting |
NCT03600558 -
Efficacy of FLAG Regimen for the Treatment of Patients With AML
|
||
Completed |
NCT02538965 -
A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 2 | |
Active, not recruiting |
NCT02333838 -
Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies
|
Phase 2 | |
Completed |
NCT01061177 -
Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome and /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase
|
Phase 4 | |
Completed |
NCT00025662 -
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS
|
Phase 2 | |
Terminated |
NCT02370888 -
Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease
|
Phase 1 | |
Recruiting |
NCT05805605 -
Allo HSCT Using RIC and PTCy for Hematological Diseases
|
Phase 2 | |
Recruiting |
NCT03080922 -
High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML
|
Phase 1/Phase 2 | |
Completed |
NCT01392989 -
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders
|
Phase 2 | |
Terminated |
NCT00306332 -
T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation
|
Phase 3 | |
Completed |
NCT00451997 -
Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes
|
Phase 2 | |
Recruiting |
NCT04310592 -
Natural Killer Cell (CYNK-001) Infusions in Adults With AML
|
Phase 1 | |
Recruiting |
NCT05458258 -
Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia
|
||
Completed |
NCT00065143 -
Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
|
Phase 2 | |
Recruiting |
NCT04789655 -
Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 1 |